Artificial Tears Market is predicted to reach USD 5.74 billion at a CAGR of 6.48% during the forecast period 2023-2032

Market Research Future (MRFR) has published on the “Global Artificial Tears Market”.

Market Highlights

The global artificial tears market is accounted to register a CAGR of 6.48% during the forecast period and is estimated to reach USD 5.74 billion by 2032.

In recent years, many objective and quantitative diagnostic methods for evaluating dry eye diseases such as tear quality metrics, tear quantity metrics, and ocular surface structural analysis have been developed. There are several products available in the market such as I-Pen Tear Osmolarity System (I-Med Pharma, Canada), Inflammadry (Quidel, US), TearLab Osmolarity System (TearLab US), and Cirrus (Carl Zeiss AG, Germany). Likewise, there have been significant advancements in diagnostic technology which are anticipated to promote medical screening for the Dry Eye Disease (DED.) The companies are actively developing new technologies to enhance their portfolio for DED diagnostics. For instance, in August 2021, AXIM Biotechnologies, Inc. (US) entered into an agreement with Advanced Tear Diagnostics (US) to acquire the technology for DED testing. Thus, the technological advancements in diagnostic testing are likely to create lucrative growth opportunities for the artificial tears market players during the forecast period.

The increasing prevalence of dry eye disease and eye inflammation, and rising preference for preservative-free products are propelling the market growth. However, the side effects and allergic reactions are expected to hamper the growth of the global market. Nevertheless, advancements in diagnostics for dry eye disease are projected to create lucrative opportunities for market players.

Key Players

MRFR recognizes the following companies as the key players in the global artificial tears market— Johnson and Johnson Vision Care (US), Allergan plc (Ireland), Alcon Plc (Switzerland), Bausch & Lomb Incorporated (Canada), Santen, Inc (Japan), URSAPHARM Arzneimittel GmbH (Germany), ROHTO Pharmaceutical CO., LTD (Japan), Similasan Corporation (US), Ocusoft (US), and Nicox (France).

Segment Analysis

The global artificial tears market has been segmented based on type, delivery mode, application, and distribution channel.

On the basis of type, the market is segmented into polyethylene glycol, propylene glycol, cellulose, glycerin, and others. The glycerin segment was attributed to holding the largest market share of over 30.31% in 2022 revenue as estimated by MRFR analysts. This is due to the rising older population and the innovations in the product range, and various benefits associated with the use of products.

Further, we estimate that the market segment would continue to pool in the largest chunk of revenue during the forecast period. It has been identified that the segment market yet witnesses continuous innovations and movements in terms of new service launches.

Based on delivery mode, the global artificial tears market has been segmented into eye drops, ointments, and sprays. The eye drops segment was expected to hold the largest market share in 2022.

On the basis of the application, the market is segmented into dry eye syndrome, allergies and infections, and others. The dry eye syndrome segment is projected to have the largest market share during the forecast period.

On the basis of the distribution channel, the market is segmented into hospital pharmacies, drug stores retail pharmacies, and online pharmacies. The hospital pharmacies segment is projected to have the largest market share during the forecast period.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Artificial Tears Market Research Report

Regional Analysis

The global artificial tears market, based on region, has been divided into North America, Europe, Asia-Pacific, and the Rest of the World. North America consists of US and Canada. The Europe artificial tears market comprises Germany, France, the UK, Italy, Spain, and the rest of Europe. The artificial tears market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the world’s artificial tears market comprises of Middle East, Africa, and Latin America.

the rising number of people with refractive errors and increasing awareness of refractive vision correction leads to demand for contact lenses are also expected to foster North America’s market growth.

Moreover, the Europe market has been persistently growing owing to a rapidly surging aging population and the increasing prevalence of ophthalmic disorders creates a demand for artificial tears in the region.

Additionally, market factors, such as growing awareness of ocular illnesses, increasing population and aging people, and rising awareness of ocular diseases in the Asia-Pacific region and are driving the region’s growth.

Furthermore, the rest of the world's patient portal market is divided into the Middle East, Africa, and Latin America. The major factors driving the growth of the artificial tears market in the region are the improving healthcare infrastructure and increasing government initiatives, improvements in developing their health systems, and improving the health status of their populations.

Key Findings of the Study

• The global artificial tears market is expected to reach USD 5.74 billion by 2032, at a CAGR of 6.48% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market, owing to the rising awareness of ocular diseases, and increasing healthcare expenditure in the Asia-Pacific region.


• Based on type, the glycerin segment was attributed to holding the largest market in 2022, with an approximate market share of around 30.31%.


• Johnson and Johnson Vision Care (US), Allergan plc (Ireland), Alcon Plc (Switzerland), Bausch & Lomb Incorporated (Canada), Santen, Inc (Japan), URSAPHARM Arzneimittel GmbH (Germany), ROHTO Pharmaceutical CO., LTD (Japan), Similasan Corporation (US), Ocusoft (US), and Nicox (France) are the key market players.